Compare RIV & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RIV | ZNTL |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 313.9M |
| IPO Year | N/A | 2020 |
| Metric | RIV | ZNTL |
|---|---|---|
| Price | $11.48 | $4.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 73.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.93 | $1.13 |
| 52 Week High | $12.56 | $6.95 |
| Indicator | RIV | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 50.58 |
| Support Level | $11.31 | $3.75 |
| Resistance Level | $11.74 | $4.34 |
| Average True Range (ATR) | 0.13 | 0.30 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 1.89 | 26.72 |
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.